MeiraGTx Holdings plc (NASDAQ:MGTX) and Cellectis S.A. (NASDAQ:CLLS) compete with each other in the Biotechnology sector. We will analyze and compare their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx Holdings plc	N/A	0.00	72.78M	-2.70	0.00
Cellectis S.A.	25.47M	29.01	82.53M	-2.11	0.00

Table 1 showcases the gross revenue, earnings per share and valuation of MeiraGTx Holdings plc and Cellectis S.A.

Profitability

Table 2 provides the net margins, return on assets and return on equity of the two firms.

	Net Margins	Return on Equity	Return on Assets
MeiraGTx Holdings plc	0.00%	0%	0%
Cellectis S.A.	-324.03%	-23%	-18.8%

Liquidity

The current Quick Ratio of MeiraGTx Holdings plc is 10.8 while its Current Ratio is 10.8. Meanwhile, Cellectis S.A. has a Current Ratio of 11.2 while its Quick Ratio is 11.2. Cellectis S.A. is better positioned to pay off its short-term and long-term debts than MeiraGTx Holdings plc.

Analyst Ratings

MeiraGTx Holdings plc and Cellectis S.A. Recommendations and Ratings are available on the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
MeiraGTx Holdings plc	0	0	0	0.00
Cellectis S.A.	0	1	0	2.00

On the other hand, Cellectis S.A.’s potential upside is 41.48% and its consensus price target is $25.

Insider and Institutional Ownership

MeiraGTx Holdings plc and Cellectis S.A. has shares owned by institutional investors as follows: 23.2% and 29.4%.

Performance

Here are the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
MeiraGTx Holdings plc	-7.85%	-6.25%	3.41%	-17%	0%	-17%
Cellectis S.A.	-12.03%	-27.86%	-25.47%	-35.88%	-21.71%	-33.55%

For the past year MeiraGTx Holdings plc has stronger performance than Cellectis S.A.

MeiraGTx Holdings plc, an integrated clinical stage gene therapy company, develops various gene therapy products for the lives of patients suffering from acquired and inherited disorders. The company focuses on various areas of unmet medical need comprising inherited retinal diseases, xerostomia, and neurodegenerative diseases. It has four ongoing clinical programs, including AAV-RPE65, which is in Phase I/II clinical trials for the treatment of RPE65-deficiency in adult and pediatric patients; AAV-RPGR that is in Phase I/II clinical trials to treat x-linked retinitis pigmentosa in adult and pediatric patients; AAV-CNGB3 that is in Phase I/II clinical trials for the treatment of achromatopsia in adult and pediatric patients; and AAV-AQP1, which is in Phase I/II clinical trials for the treatment of patients with grade 2 or 3 radiation-induced xerostomia. The company also has a pipeline of preclinical and research programs in other indications. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The companyÂ’s products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.